pulmonary shunt
Conditions
Interventions
Group E1:At induction, esketamine was injected intravenously at 0.25mg/kg, and after induction, it was injected continuously at 0.5mg/kg/h
Group E2:At induction, esketamine was injected intravenously at 0.5mg/kg, and after induction, it was injected continuously at 0.5mg/kg/h
Group C:Give an equal amount of saline
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: ASA?~? level; Selective thoracoscopic pneumonectomy was performed. Age 18-70 years old; Obtain informed consent from patients and their families; 18=BMI=30.
Exclusion criteria
Exclusion criteria: (1) Patients allergic to any drug in the trial; (2) Patients at risk of elevated intracranial pressure; (3) Patients with poorly controlled or untreated hypertension (resting systolic/diastolic blood pressure exceeding 180/100 MMHG); (4) Patients with hyperthyroidism and poor control; (5) serious heart and lung diseases and liver and kidney dysfunction; (6) A history of mental illness or drug abuse; (7) Refusing to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Qs/Qt(Intracapulmonary shunt); | — |
Secondary
| Measure | Time frame |
|---|---|
| Cdyn(Dynamic compliance);Cst(Static compliance);Vd/Vt(Dead space fraction);SPO2(oxygen saturation);PaCO2/FiO2(oxygenation index); | — |
Countries
China
Contacts
Public ContactJin Gao
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed